NeuShen Therapeutics, a Shanghai-and-Boston biotech led by a veteran transpacific drug developer, raised more than $80 million to advance three clinical-stage brain-health drugs. The funding, disclosed as a Series B, is intended to support development progress across the company’s late clinical pipeline. NeuShen’s capital raise highlights sustained investor willingness to fund CNS pipelines, particularly for programs already in clinical stages where near-term proof of biology and development milestones are clearer than in preclinical work. For the sector, the deal adds to the competitive landscape of brain-health therapeutics that increasingly compete on differentiation in mechanism, patient selection, and outcome measures. The company’s transpacific leadership structure also reflects how cross-border clinical development capabilities are becoming a practical requirement for scaling timelines and regulatory planning in neurotherapeutics.